News & Publications

MiRXES to Collaborate with Johnson & Johnson Innovation LLC and Janssen Pharmaceutica to Advance Biomarker Diagnostics for Lung Cancer

Singapore, 10 January 2018 – MiRXES has announced a strategic collaboration with Johnson & Johnson Innovation and Janssen Pharmaceutica NV to further develop a novel circulating miRNA diagnostic test, with the aim to improve the detection of early-stage lung cancer. This is among the 15 new strategic collaborations by Johnson & Johnson Innovation to drive innovation in science and technology to address areas of high unmet medical needs.

Dr Lihan Zhou, Co-founder and CEO of MiRXES said, “Lung cancer is the most prevalent and deadliest cancer globally, with close to 2 million new cases annually. Prognosis remains poor due to late manifestation and diagnosis. We are excited to collaborate with the world’s largest healthcare innovation company to advance the science and technology of miRNA as a novel solution for lung cancer screening and diagnosis. The goal is to develop and commercialize an accurate, affordable and actionable blood test to detect lung cancer at early and asymptomatic stage.”

Dr Zhou will present the development roadmap of MIRXES’ lung and other cancer miRNA assays at the reputed Biotech Showcase 2018 during the JPM week at San Francisco

Details of MiRXES presentation at Biotech Showcase™ are as follows:

Date:​ Wednesday, 10 January 2018

Time: ​10:45 am (PST)

Room:​ Hilton/ Yosemite C

Venue:​ Hilton San Francisco Union Square Hotel, ​333 O’Farrell Street, San Francisco, CA (United States)

For more information, please contact:

Marienelle Castelino, REDHILL,

Natalie Chua, REDHILL,

Blog Image

MiRXES founders won Scientist-Entrepreneur Award from A*Star

MiRXES founders are awarded as inspiring Scientist-Entrepreneurs by A*Star. Prof. Too Heng Phon, Dr.Zhou Lihan and Dr.Zou Ruiyang started the company from a university lab; and strived to grow the innovative technology with the support from A*Star. The award recognizes MiRXES' effort of bringing the technology to the market and translating innovative solutions from bench to bedside.

MiRXES won 1st runner up in BioSingapore Innovative Biomedical Company

MiRXES focuses on proprietary ultra-sensitive quantitative technology to detect microRNA cancer biomarkers. Currently, MiRXES is running the world's largest prospective clinical studies for early stage gastric, lung and breast cancer diagnostics utilizing the miRNA biomarkers. This award recognises companies that are on the forefront of innovation across the Singapore Biosciences Industry and celebrates the spirit of innovation and creative business solutions in the highly competitive biomedical and medical technology industry.

Read More
Blog Image

MiRXES Holds Talks in BIO Europe Spring

MiRXES networking and meeting with Pharma, MedTech and CRO customers and collaborators at BIO Europe Spring in Barcelona.
If you missed meeting us there, be sure to meet us at BIO in San Diego and The Liquid Biopsy Summit in San Francisco this June.

Blog Image

MiRXES Won Most Promising Start Up in OCBC Emerging Enterprice Awards (EE2016)

MiRXES' efforts to revolutionize cancer detection was recognized at the 2016 Emerging Enterprise Awards (EE 2016) in Singapore. Professor Too Heng-Phon accepted the Most Promising Startup trophy from Dr Koh Poh Koon, Minister of State for National Development and Trade and Industry, at a gala dinner held at St Regis Hotel on 16 Sep 2016.
The annual award is organised by The Business Times and OCBC Bank to celebrate entrepreneurial businesses in Singapore.

Read More

Johnson and Johnson Announces Collaboration with MiRXES on Gestational Diabetes

GDM is diagnosed when carbohydrate intolerance (hyperglycemia) is developed or recognized during pregnancy for the first time. Consequences for mother and child can be severe and include increased risks of birth trauma, jaundice, respiratory distress syndrome, macrosomia, cesarean section, and maternal hypertensive disorder. Longer term, 30-50 percent of women with GDM develop type 2 diabetes (T2D) and children have an increased risk of obesity and T2D, as well as asthma and behavioral disorders. Using biomarkers to segment the population at high risk, the GDM Venture team is focused on developing disease interception solutions that address the root causes of GDM.

Read More

MiRXES Gastric Cancer Kit Featured in Singapore’s National News

A blood test to assess early-stage stomach cancer, a major killer here, could be rolled out in local hospitals as soon as next year. Instead of going for an uncomfortable endoscopy to see if they are at risk, patients can first take the blood test to see whether more detailed tests are needed.

The diagnostic kit is the brainchild of MiRXES - a spin-off by researchers from the Agency for Science, Technology and Research (A*Star). With just a few drops of blood, doctors are able to detect accurately whether a patient has developed early-stage gastric cancer.

Read More

MiRXES launches Epstein-Barr Virus (EBV) microRNA Assays (BART miRNAs)

Read More